Business Wire

A2RL

23.4.2024 17:55:33 CEST | Business Wire | Press release

Share
Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27

On Saturday, April 27th, Abu Dhabi will host a groundbreaking event, welcoming 10,000 spectators to witness the inaugural ASPIRE Abu Dhabi Autonomous Racing League (A2RL) at the iconic Yas Marina Circuit. This brand-new autonomous racing competition marks a significant milestone in motorsport history, billed as the largest league of its kind globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423980323/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27 (Photo: AETOSWire)

Eight teams will compete: Code19 Racing (one of the first independent autonomous racing entity from the USA), Constructor University (based in Germany and Switzerland), Fly Eagle (representing Beijing Institute of Technology from China and Khalifa University from the UAE), HUMDA Lab (a member of the Széchenyi István University Group from Hungary), KINETIZ (a collaboration between Singapore Nanyang Technological University and Kintsugi based in the UAE), PoliMOVE (representing Politecnico di Milano from Italy), UNIMORE (also from Italy - University of Modena and Reggio Emilia), and Technical University of Munich - TUM (from Germany), vying for a substantial prize purse of US$ 2.25 million.

The participating teams of coders and engineers will each have exclusive access to identical Dallara Super Formula SF23 cars, made possible through a partnership with Japan Race Promotions. These cars will be autonomized with autonomous racing stacks developed and integrated by the Technology Innovation Institute (TII). The sole variable lies in how each team utilizes their coding skills, AI algorithms, and machine learning software development expertise to teach their cars how to drive. Currently recognized as the fastest open-wheel race car in the world after Formula One, these cars can reach speeds of up to 300 km/h.

For the first time, the race format is poised to feature four autonomous cars driving on the racetrack simultaneously – a feat never before attempted. In a series of pre-qualifying races, the finale will showcase the top performers from the Lap Test and Speed Test, advancing to a final Overtaking Challenge to determine the ultimate winner. Additionally, an AI vs Human car race will unfold, with the Technology Innovation Institute (TII) embracing the electrifying challenge of pitting their autonomous car against former F1 driver – Daniil Kvyat. TII will aim to get as close as possible to the human lap time and will also demonstrate the autonomous car’s ability to drive without GPS assistance.

H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council - ASPIRE’s parent entity, and Advisor to the UAE President on Strategic Research and Advanced Technology Affairs, said: "In pushing the boundaries of technology under extreme conditions, we uncover new frontiers in science. This reimagined racing paradigm harnesses the pinnacle of coding skills, AI algorithms, and software development prowess — the very skill sets of the future. By leveraging these capabilities, we pave a path at the forefront of research and development, propelling Abu Dhabi to become a pivotal global hub for innovation."

ADNOC has come on board as title sponsor, providing crucial support, underscoring the widespread enthusiasm for advancing autonomous racing technology. H.E. Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, and Group MD & CEO of ADNOC, added: "As we navigate the path to UAE's industrial future, our commitment to in-country value and technological advancement stands unwavering. A2RL epitomizes our dedication to integrating cutting-edge technology including AI, driving competitiveness and economic growth across sectors. For decades, ADNOC has invested in the latest technology and innovation – from the control room, to the board room - to deliver the modern energy that powers our lives."

Organizer of A2RL, ASPIRE CEO Stephane Timpano said: "A2RL is more than just a race — it's a platform for testing and optimizing autonomous vehicle technologies, enhancing safety and reliability on public roads. With the support of local and international partners, we're bringing the mobility future - closer." The inaugural race has attracted a diverse array of sponsors, each contributing their expertise and resources to ensure the success of the development of the cutting-edge autonomized cars. Leading partners, such as Du, DMT, AWS, and Mubadala, have played pivotal roles in shaping the event’s trajectory, with media partners such Motorsports, Inc. Arabia, FastCompany Middle East, and What’s On, amplifying A2RL’s visibility.

Technical partners, including Dallara, Danisi Engineering, Meccanica 42, Kistler, Seyond, Eventagrate, Live in Five, Focal Point VR and Vislink, have lent their specialized knowledge to elevate the event's innovation and performance standards.

An exclusive Fan Zone promises an elevated experience for families, motorsport fans, and tech enthusiasts alike. With tailored activities, guests can immerse themselves in cutting-edge tech and gaming, including a captivating VR zone and the AI museum – Raceum. From 16:00 (GST) on April 27, young students from the A2RL STEM Competition will showcase their coding skills on 1:8 scale autonomous racing cars, with 18 schools competing to add excitement. The night concludes at 23:00 (GST), with activities including a podium ceremony for the winners, fireworks, a drone show, and an after-show concert with DJ Andre Soueid.

For those unable to attend in person, the excitement of Race Day will be accessible through various live streaming channels, including A2RL’s official YouTube and Twitch channels, motorsport.tv and the A2RL app. Interested parties are invited to visit the A2RL website and monitor social media channels for updates regarding the program schedule and details on viewing the race in their respective regions.

The inaugural A2RL event is part of Abu Dhabi Mobility Week, running from April 24 to May 1.

Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423980323/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye